It is expected that, in the presence of CD8+ T lymphocytes, PD1+ tumors are more responsive compared to PD1-negative tumors (194–196), and anti-tumor therapeutic decisions may be guided by the results of immunohistochemical tests for PDL1 expression (197). Here, CD8A is linked to neoplasm.